Clinical ResearchVascular Response of the Segments Adjacent to the Proximal and Distal Edges of the ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold: 6-Month and 1-Year Follow-Up Assessment: A Virtual Histology Intravascular Ultrasound Study From the First-in-Man ABSORB Cohort B Trial
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Gogas wishes to acknowledge the American College of Cardiology Foundation for the International Society of Cardiovascular Translational Research Award, and Hellenic Cardiological Society and Hellenic Heart Foundation for providing funding support. Dr. Chevalier is a consultant for Abbott Vascular. Prof. Dudek has received research grants or served as consultant/advisory board member for Abbott, Adamed, AstraZeneca, Biotronik, Balton, Bayer, BBraun, BioMatrix, Boston Scientific, Boehringer-Ingelheim, Bristol-Myers Squibb, Cordis, Cook, Eli Lilly & Co., EuroCor, GlaxoSmithKline, Invatec, Medtronic, The Medicines Company, MSD, Nycomed, Orbus-Neich, Pfizer, Possis, Promed, Sanofi-Aventis, Siemens, Solvay, Terumo, and Tyco. Dr. Windecker received research grants to the institution from Abbott, Biotronik, Biosensors, Boston Scientific, and Cordis. Dr. Ormiston was on the advisory board of and received minor honoraria from Abbott Vascular and Boston Scientific. Drs. Miquel-Hebert and Rapoza and Ms. Dorange are employees of Abbott Vascular. Michael Kutcher, MD, served as Guest Editor for this paper.
All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.